Email Alert | RSS

Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (10): 987-992.doi: 10.3969/j.issn.1000-6621.2021.10.002

• Guideline·Standard·Consensus • Previous Articles     Next Articles

Expert consensus on the study of early bactericidal activity of new anti-tuberculosis drugs

Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute , Editorial Board of Chinese Journal of Antituberculosis   

  • Received:2021-08-03 Online:2021-10-10 Published:2021-10-11

Abstract:

The tuberculosis epidemic is still severe, and new anti-tuberculosis drugs are urgently needed. Clinical trials of new drugs are the most important stage of new drug development. Early bactericidal activity (EBA) is the first step in clinical study of new anti-tuberculosis drugs used in the treatment of tuberculosis patients, and it is also the key of clinical evaluation of the single anti-tuberculosis drug and a new regimen. In order to standardize and better promote the development of new anti-tuberculosis drugs in China, after repeated discussions by experts in the field of tuberculosis clinical and basic research organized by Beijing Chest Hospital affiliated to Capital Medical University and the Editorial Board of Chinese Journal of Antituberculosis, the Expert consensus on the study of early bactericidal activity of new anti-tuberculosis drugs has been formulated on the significance, design, implementation, and influencing factors of the EBA study on the new anti-tuberculosis drugs.

Key words: Tuberculosis, Drug evaluation, Early bactericidal activity, Consensus development conferences as topic